Changes in cervical intraepithelial neoplasia rates and cervical cancer screening following introduction of the HPV vaccine in the US

February 11, 2019

Share article

The authors were interested in the changes in rates of cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ (CIN2+) following the introduction of the human papillomavirus (HPV) vaccine and changes to cervical cancer screening recommendations. They conducted population-based laboratory surveillance for CIN2+ in in five states of the US between 2008-2015. A total of 16,572 CIN2+ cases were reported during that time. Among women aged 18-20 and 21-24 years, CIN2+ rates declined in all sites examined, while in women aged 25-29, 30-34 and 35-39 years, the trends in rates were different across sites. The authors found that the percentage of women screened annually declined in all sites and age groups. Compared with 2008-2009, rates among screened women were significantly lower for all three time periods examined in women aged 18-20 years: 2010-2011 incidence rate ratio [IRR] 0.82 (95%CI 0.67-0.99), 2012-2013 IRR 0.63 (95%CI 0.47-0.85), and 2014-2015 IRR 0.44 (95%CI 0.28-0.68). For women aged 21-24 years the rates were significantly lower for the latter two time periods only: 2012-2013 IRR 0.86 (95%CI 0.79-0.94), and 2014-2015 0.61 (95%CI 0.55-0.67). However, rates among screened women increased for age groups 25-29, 30-34 and 35-39 years. Therefore from 2008-2015, both CIN2+ rates and cervical cancer screening declined in women aged 18-24 years.

Read more here

Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, et al. ISSN: Clin Infect Dis; doi: 10.1093/cid/ciy707


Added: February 11, 2019